Living reference work entry
Cholangiocarcinoma refers to malignancy within the biliary duct system (Bile Duct Neoplasms) and is distinct from gallbladder cancer. Cholangiocarcinomas generally have features of biliary tract epithelium, such as a glandular appearance, small regular nuclei, and scant cytoplasm. Tumor cells often express cytokeratins, mucin, and cancer-associated antigen 19-9, a carbohydrate antigen that is used as a tumor marker in serum. It is thought to be a sialylated Lewis blood group antigen. CA19-9 levels are elevated in many gastrointestinal malignancies including cholangiocarcinoma and pancreatic cancer, as well as some nonmalignant conditions such as cholangitis and peritoneal inflammation/infection. Patients who have a genetic deficiency in a fucosyltransferase specified by the Le gene are Lewis a-b- and are unable to make this antigen; thus CA19-9 testing in Lewis a-b- patients can be falsely negative.
95 % of bile duct...
KeywordsEpidermal Growth Factor Receptor Primary Sclerosing Cholangitis Gallbladder Cancer Intrahepatic Cholangiocarcinoma Endoscopic Retrograde Cholangiography
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- de Groen PC, Gores GJ, LaRusso NF et al (1999) Biliary tract cancers. N Engl J Med 341:1368–1378Google Scholar
© Springer-Verlag Berlin Heidelberg 2014